Advice
Recommended for use within NHS Scotland
REASONS FOR ADVICE
Escitalopram has been shown to be as effective as citalopram in short-term use and the health economic model submitted suggests that it is also cost-effective. However, the resource usage assumptions and clinical evidence underpinning the model are not robust and no clear benefits are demonstrated over the parent product - citalopram or other effective and cheaper agents.
Download detailed advice26KB (PDF)
Medicine details
- Medicine name:
- Escitalopram (Cipralex®)
- SMC ID:
- 17/02
- Indication:
- Major depressive episodes
- Pharmaceutical company
- Lundbeck Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 07 March 2003